ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: NCAB To Meet Jan. 15-17; UCLA To Compete For Clinical Neutron Therapy Contract

January 5, 1979

In Brief: Subcommittee Adds $16-18 Million o NVI Budget; Upton Might Leave If Bill Fails

May 25, 1979

Test May Identify Predictors For Recurrence Post-Surgery

January 28, 2011

White House Backs Down FY 86 Cuts, Says Now They Will Be Limited To Trimming Indirect Costs

January 10, 1986

FDA, NCI, CMS Announce Biomarker Initiative; First Project To Validate FDG-PET As Predictor Of Tumor Response In Non-Hodgkin’s Lymphoma.

February 17, 2006

Sen. Mack Seeks Research Funding For Shark Cartilage

July 29, 1994